Rating Change
B. Riley Securities reiterated its Buy rating on Zymeworks Inc. (NASDAQ:ZYME) on August 10, 2026.
B. Riley Securities reiterated its Buy rating on Zymeworks Inc.

At publication ·
Zymeworks Inc. (NASDAQ:ZYME) · reiterate
At a glance
B. Riley Securities reiterated its Buy rating on Zymeworks Inc. (NASDAQ:ZYME) on August 10, 2026.
Zymeworks Inc. operates in the Healthcare sector. The stock currently trades at $24.16 with a market capitalization of $1.9B.
Analyst coverage from B. Riley Securities provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zymeworks Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 10, 2026 | B. Riley Securities | Buy | N/A |
| Aug 07, 2026 | Wells Fargo | Overweight | N/A |
| Aug 07, 2026 | Truist Securities | Buy | N/A |
| Aug 05, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 07, 2026 | Truist Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ZYME Stock Page
A rating of Buy from B. Riley Securities reflects the analyst's outlook on Zymeworks Inc. (NASDAQ:ZYME). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZYME forecast page.
Current market data
NASDAQ · ZYME
$26.44
Down: -$0.20 · -0.74%
Live quote updated
Keep reading